Broome Oncology

Lynparza-Avastin Maintenance Delays Progression of Ovarian Cancer

Results from the phase III PAOLA-1 clinical trial in women with advanced ovarian cancer evaluating maintenance therapy with Lynparza (olaparib) plus Avastin (bevacizumab) compared to Avastin alone in women with or without BRCA gene mutations have been released and the combination delays cancer progression. (1)

About Ovarian Cancer

Ovarian cancer is the eighth most common cause of death from cancer in women worldwide. In 2018, there were nearly 300,000 new cases diagnosed and around 185,000 deaths.1 Most women are diagnosed with advanced (Stage III or IV) ovarian cancer and have a five-year survival rate of approximately 30%.(2) For newly-diagnosed advanced ovarian cancer, the primary aim of treatment is to delay progression of the disease for as long as possible and maintain the patient’s quality of life with the intent of achieving complete remission or cure. (3-6)

About PAOLA-1

PAOLA-1 is a randomized phase III clinical trial testing the effectiveness and safety of Lynparza added to Avastin compared to Avastin alone, as a 1st-line maintenance treatment for newly-diagnosed advanced stage III-IV high grade serous or endometroid ovarian, fallopian tube, or peritoneal cancer patients who had a complete or partial response to 1st-line treatment with platinum-based chemotherapy and Avastin.

The trial met its primary endpoint in the intent-to-treat population with a statistically-significant and clinically-meaningful improvement increasing the time women taking Lynparza plus Avastin survived without disease progression or death compared to those taking Avastin alone. The full trial results, including biomarker sub-group analyses, will be presented at a forthcoming medical meeting.

Connect with ovarian cancer patients for support and information here.

Following positive results from the SOLO-1 trial for women with a BRCA gene mutation, the PAOLA-1 trial marks another positive phase III trial for Lynparza as a 1st-line maintenance treatment for women with advanced ovarian cancer.

References:

  1. https://www.astrazeneca.com/media-centre/press-releases/2019/lynparza-phase-iii-paola-1-trial-met-primary-endpoint-as-1st-line-maintenance-treatment-with-bevacizumab-for-advanced-ovarian-cancer-14082019.html
  2. The World Health Organization. IARC. Globocan 2018. Available at: http://gco.iarc.fr/ Accessed July 2019.
  3. National Cancer Institute. (2019). Cancer Stat Facts: Ovarian Cancer Available at: https://seer.cancer.gov/statfacts/html/ovary.html Accessed August 2019.
  4. Moore K et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. Presented at ESMO October 2018.
  5. Raja, F. A., Chopra, N. & Ledermann, J. A. 2012. Optimal first-line treatment in ovarian cancer. Ann. Oncol Off. J. Eur. Soc. Med. Oncol. 23 Suppl 10, x118-127.
  6. NHS Choices, Ovarian Cancer Available at: https://www.nhs.uk/conditions/ovarian-cancer/treatment/ Accessed July 2019.
  7. Ledermann.et al. 2013. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice.

Copyright © 2019 CancerConsultants. All Rights Reserved.